Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first‐ and second‐generation NS5A inhibitors-Reference-Cited by-同舟云学术

Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first‐ and second‐generation NS5A inhibitors

Published:2021-03-25 Issue:8 Volume:93 Page:4975-4981
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J Med Virol

Author:

Fedorchenko Sergii V.¹^ORCID,Martynovych Tatiana¹,Klimenko Zhanna¹,Solianyk Iryna¹

Affiliation:

1. Department of Viral Hepatitis and AIDS The L.V. Gromashevskyi Institute of Epidemiology and Infectious Disease Kiev Ukraine

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.26935

Reference30 articles.

1. Estimating HCV disease burden - volume 3 (editorial)

2. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modeling study;Black S;Lancet,2017

3. Treatment of patient with chronic hepatitis C infection in Lombardia: a report by the Lombardia Hepatitis Network;Aghemo A;Eur Rev Med Pharmacol Sci,2016

4. Effectiveness, safety and clinical outcomes of direct‐acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real‐world cohort;Crespo J;J Hepatol,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks;2024-04-10

2. Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing NS5A inhibitors with sofosbuvir/velpatasvir plus ribavirin for 24 weeks;Journal of Clinical Virology Plus;2023-06